Dermatology Times

AUGUST 8, 2024

Key opinion leaders examine safety concerns and adverse event trends in psoriasis treatments, discussing how these factors influence decisions to discontinue therapy and transition patients to alternative interventions.

Safety 36

Safety Treatments Therapy 36

US Dermatologt Partners

MARCH 27, 2024

Red light therapy is considered one of the newest and most innovative skin rejuvenation procedures available. Dermatology Partners in Cedar Park, Texas , “ Red light therapy is so new that the dermatologic community hasn’t even settled on one name for it. What is Red Light Therapy?

Therapy 41

Therapy Treatments Dermatology Collagen 41

The Dermatology Digest

NOVEMBER 20, 2024

Kimball, MD, MPH, Beth Israel Deaconess Medical Center and Professor of Dermatology at Harvard Medical School, Boston, MA, in s news release. “In the Phase 3 clinical studies, patients treated with bimekizumab-bkzx achieved deep and sustained clinical responses up to 48 weeks.” Clinical responses were sustained to Week 48.

Safety 64

Safety Sustainability Clinic Medical 64

Dermatology Times

NOVEMBER 1, 2024

VYNE Therapies announces that aNSV patients saw disease improvement without serious adverse effects.

Safety 56

Safety Therapy 56

The Dermatology Digest

NOVEMBER 14, 2024

The interleukin 17A (IL-17A) and IL-17F blocker was approvedfor the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy in Oct. Fatigue was assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue subscale (FACIT-Fatigue).

Sustainability 64

Sustainability Safety Clinic Therapy 64

Dermatology Times

JUNE 4, 2024

This week’s collection of the latest dermatologic studies includes the use of digital communication for patients with hidradenitis suppurativa (HS), rituximab for pediatric patients with pemphigus, a case report of primary oral extramammary Paget disease, and the efficacy and safety of LAight therapy for HS.

Safety 69

Safety Therapy Dermatology 69

The Dermatology Digest

AUGUST 20, 2024

Food and Drug Administration (FDA) approved apremilast for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or systemic therapy. The adverse events were consistent with the known safety profile of Otezla in adult patients.

Safety 74

Safety Injections Therapy Treatments 74

The Dermatology Digest

APRIL 7, 2024

The new ladder divides nonsteroidal medication classes into treatments for exacerbations and maintenance therapies in an escalating order based on their increasing potential for adverse effects. The new topical therapies constitute the lower rungs of the therapeutic ladder and can be used for both exacerbations and maintenance.

Treatments 77

Treatments Dermatitis Therapy Medical 77

Dermatology Times

NOVEMBER 4, 2024

Researchers stated the dual-action therapy could offer a promising approach to treat progressive non-segmental vitiligo.

Safety 41

Safety Therapy 41

The Dermatology Digest

NOVEMBER 15, 2024

If approved, dupilumab would be the first targeted therapy for CSU in a decade. Safety results in all LIBERTY-CUPID phase 3 studies were generally consistent with the known safety profile of dupilumab. Safety results in all LIBERTY-CUPID phase 3 studies were generally consistent with the known safety profile of dupilumab.

Safety 28

Safety Therapy Clinic Dermatology 28

The Dermatology Digest

FEBRUARY 11, 2024

By Ted Rosen, MD According to the results of a recently published investigation in JAMA Dermatology 1 , the Janus kinase (JAK) inhibitors currently utilized for a variety of skin diseases appear safe in our dermatological population. Ireland PA, Jansson N, Spencer SKR. January 31, 2024. doi:10.1001/jamadermatol.2023.5509

Safety 74

Safety Dermatology Clinic Therapy 74

The Dermatology Digest

FEBRUARY 16, 2024

One of the biggest challenges in CAR T-cell therapies is the scarcity of suitable tumor targets,” says study author Cristina Puig-Saus, PhD, assistant professor of medicine at the David Geffen School of Medicine at UCLA, in a news release. “One

Therapy 36

Therapy Clinic Safety Treatments 36

The Dermatology Digest

JUNE 5, 2024

The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks. We believe that VYN201 has the potential to become a valuable and differentiated therapy for patients with vitiligo.

Safety 73

Safety Office Facials Therapy 73

The Dermatology Digest

AUGUST 30, 2024

The safety profile of pembrolizumab in this trial was consistent with the drug’s established safety profile. The primary endpoint is RFS, and key secondary endpoints include OS and safety. The post Keytruda Disappoints in Phase III SCC Trial; Merck Halts Study appeared first on The Dermatology Digest.

Surgery 36

Surgery Safety Therapy Innovations 36

Dermatology Times

JUNE 2, 2024

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Dermatitis 52

Dermatitis Therapy Safety Treatments 52

The Dermatology Digest

SEPTEMBER 9, 2024

In a preliminary review by an independent data safety committee, the ongoing study of 60 patients demonstrated a much lower incidence and severity of side effects as well as improved efficacy for preventing Raynaud’s attacks, when compared to published reviews of current therapies.

Portfolios 36

Portfolios Dermatology Injections Marketing 36

The Dermatology Digest

FEBRUARY 16, 2024

for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. The safety profile of dupilumab in CSU was generally consistent with the known safety of Dupixent in its approved dermatological indications.

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

Dermatology Times

MARCH 14, 2024

A panel of experts discusses unique needs of patients with skin of color, look at long-term safety and efficacy of emerging oral treatments, and delve into combining topicals with systemic therapies.

Management 74

Management Safety Therapy Treatments 74

Dermatology Times

JANUARY 8, 2024

Systemic corticosteroids are often used as primary therapy for PG, but alternatives should be considered for their favorable safety profile.

Clinic 78

Clinic Management Safety Treatments 78

The Dermatology Digest

NOVEMBER 12, 2024

And the winners are… The 2024 recipients of the American Society for Dermatologic Surgery’s (ASDS) annual awards were recognized during the Society’s Annual Membership Meeting during the ASDS Annual Meeting in Orlando, FL. He spoke about, “Innovations in Dermatologic Surgery: From the Microscope to the Bedside.” Lawrence M.

Surgery 36

Surgery Innovations Dermatology Education 36

The Dermatology Digest

SEPTEMBER 12, 2024

In the confirmatory phase 3 study (LIBERTY-CUPID Study C), dupilumab met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines. At 24 weeks, efficacy among patients receiving Dupixent compared to placebo was as follows: 8.64-point

Safety 36

Safety Office Medical Dermatology 36

The Dermatology Digest

MAY 8, 2024

The safety profile of subcutaneous nivolumab was consistent with the IV formulation. The pharmacokinetics, efficacy, and safety results from CheckMate -67T were presented at the American Society of Clinical Oncology (ASCO) 2024 Genitourinary Cancers Symposium. “An

Safety 36

Safety Therapy Injections Dermatology 36

The Dermatology Digest

OCTOBER 21, 2024

Currently, the standard of care predominantly involves corticosteroids, topical therapies, traditional disease-modifying anti-rheumatic drugs (tDMARDs), and, in more severe or refractory cases, intravenous immunoglobulin (IVIg) or off-label biologics, underscoring the growing unmet need for novel therapeutic options to treat this condition.

Treatments 41

Treatments Injections Therapy Management 41

The Dermatology Digest

APRIL 4, 2024

The safety profile of Bimzelx was consistent with previous studies with no new safety signals observed. in October 2023 for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. In addition, improvements increased for patients in these studies over 48 weeks.

Safety 57

Safety Injections Clinic Therapy 57

The Dermatology Digest

MARCH 12, 2024

may help treat milder hidradenitis suppurativa (HS), according to new phase 2 data presented at the annual meeting of the American Academy of Dermatology in San Diego, CA. Ruxolitinib cream could be used both as monotherapy or potentially in combination with other therapies for HS in the future, she says. “We

Therapy 69

Therapy Safety Dermatology Treatments 69

Online Laser Training

OCTOBER 11, 2019

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

Hospital 78

Hospital Safety Clinic Training 78

Online Laser Training

OCTOBER 11, 2019

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

Hospital 78

Hospital Safety Clinic Training 78

The Dermatology Digest

SEPTEMBER 20, 2024

s Investigational Device Exemption (IDE) application to initiate a multi-center study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (cSCC) in immunocompromised patients using Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT). Food and Drug Administration (FDA) has approved Alpha Tau Medical Ltd.’s

Office 74

Office Safety Clinic Medical 74

The Dermatology Digest

JUNE 14, 2024

ICP-332 achieved multiple efficacy endpoints in the China Phase II study of patients with moderate-to-severe AD and demonstrated an “outstanding” and safety profile. ICP-332 showed better efficacy profile across different classes and mechanisms of action of therapies for the treatment of AD patients although this was not a head-to-head study.

Dermatitis 36

Dermatitis Marketing Safety Innovations 36

The Dermatology Digest

OCTOBER 26, 2024

“These findings indicate that upadacitinib may address an unmet medical need in patients with moderate-to-severe AD who do not achieve an adequate response while taking dupilumab,” conclude researchers who were led by Christopher Bunick, MD, PhD, an Associate Professor of Dermatology at Yale University in New Haven, CT.

Dermatitis 36

Dermatitis Treatments Pharmaceutical Eczema 36

The Dermatology Digest

MAY 22, 2024

The BLA is seeking approval of subcutaneous nivolumab across all previously approved adult, solid tumor nivolumab indications as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab (Yervoy , BMS ) combination therapy, or in combination with chemotherapy or cabozantinib.

Safety 36

Safety Therapy Dermatology 36

Aesthetics Advisor

AUGUST 19, 2023

Nevertheless, PRP and exosome-related therapies are not yet established as standard treatments, given their relatively recent emergence. Because the human body is specially equipped to heal itself, and regenerative therapies tap into this powerful ability. There’s tremendous excitement in the hair world and dermatology.”

Therapy 36

Therapy Injections Medical Treatments 36

The Dermatology Digest

OCTOBER 30, 2024

Grants of up to $35,000 will be awarded to promising projects in the field of clinical, biological or pharmacological research linked to dermatology. Ultimately, our aim is to improve public health outcomes and raise awareness about the critical importance of sun safety in our communities,” say Drs. Nahar and Huynh in a news release.

Sun Protection 36

Sun Protection Dermatology Safety Innovations 36

The Dermatology Digest

OCTOBER 24, 2024

APG777, in single doses up to 1,200mg or multiple doses of 300mg, showed a well-tolerated safety profile. The post AD Pipeline Watch: Apogee’s APG777 Continues to Shine in Phase 1 AD Study appeared first on The Dermatology Digest. The company expects to report 16-week topline data from Part A of the trial in the second half of 2025.

Sustainability 36

Sustainability Dermatitis Safety Clinic 36

The Dermatology Digest

FEBRUARY 14, 2024

This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023. Nemolizumab was generally well tolerated and its safety profile was similar to placebo across the OLYMPIA and ARCADIA clinical trial programs.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

NOVEMBER 6, 2024

This could help doctors better predict which therapies will work best for each patient. He will test ONT01, which has shown promising results in mouse models, in a phase 1b trial to assess its safety in people with lupus. This trial could open the door to a new class of treatments that target lupus at the molecular level.

Hospital 36

Hospital Therapy Management Networking 36

Lipgloss and Aftershave

NOVEMBER 1, 2024

Krystal Briglia, L+A Medical + Wellness Editor Dr. Krystal Briglia of Triada Integrative Medicine + Wellness is a board-certified nurse practitioner specializing in aesthetic dermatology, integrative medicine, and wellness. Journal of Dermatological Science. Journal of the American Academy of Dermatology. Dermatologic Therapy.

Chemical Peels 52

Chemical Peels Hyperpigmentation Vitamin C Microneedling 52